Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant virus encoding one or more heterologous proteins...
Reexamination Certificate
2006-06-20
2006-06-20
Mosher, Mary E. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant virus encoding one or more heterologous proteins...
C424S229100, C424S230100, C424S231100, C424S093200, C424S093210, C424S278100, C424S205100, C435S355000, C435S372000, C435S325000, C435S235100, C435S320100
Reexamination Certificate
active
07063851
ABSTRACT:
A method of stimulating an immune response in a human or animal subject, which method comprises administering to a subject in need thereof an effective amount of an attenuated herpes virus which:(i) lacks a functional vhs gene, or a functional equivalent thereof;(ii) lacks a functional ICP47 gene, or a functional equivalent thereof; and(iii) is incapable of expressing a substantial amount of functional ICP22, or a functional equivalent thereof, in mammalian dendritic cells.
REFERENCES:
patent: 6713067 (2004-03-01), Coffin
patent: 2004/0219167 (2004-11-01), Coffin
patent: WO 94/03207 (1994-02-01), None
patent: WO 97/13866 (1997-04-01), None
patent: WO 98/04726 (1998-02-01), None
patent: WO 98/30707 (1998-07-01), None
patent: WO 98/51809 (1998-11-01), None
patent: WO-98/51809 (1998-11-01), None
patent: WO 99/60145 (1999-11-01), None
patent: WO-00/08191 (2000-02-01), None
patent: WO 00/08191 (2000-02-01), None
patent: WO 00/08891 (2000-02-01), None
patent: WO 01/77358 (2001-10-01), None
Krisky et al Gene Therapy 5:1517-1530, 1998.
Walker et al, Vaccine 16(1):1-5 (1998).
Walker et al, “Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice”, Vaccine 16(1):6-8 (1998).
Strelow et al, “Role of the Virion Host Shutoff (vhs) of Herpes Simplex Vi9rus Type 1 in Latency and Pathogenesis”, Journal of Viroloty 69:6779-6786 (1995).
Geiss et al, “Disruption of Virion Host Shutoff Activity Improves the Immunogenicity and Protective Capacity of a Replication-Incompetent Herpes Simplex Virus Type 1 Vaccine Strain”, Journal of Virology 74(23):111137-11144 (2000).
Huard et al, “Gene transfer to muscle using herpes simplex virus-based vectors”, Neuromuscular Disorders 7(5):299-313 (1997)—Abstract.
Coffin et al, “Pure populations of transduced primary human cells can be produced using GFP expressing herpes virus vectors and flow cytometry” Gene Therapy 5:718-722 (1998).
Coffin et al, “Gene delivery to the central and peripheral nervous systems of mice using HSV1 ICP34.5 deletion mutant vectors” Gene Therapy 3:886-891 (1996).
Walker et al, Vaccine 16:1-5 (1998).
Walker et al, “Postexposure vaccination with a virion host shutoff defective mutant reduces UV-B radiation-induced ocular herpes simplex virus shedding in mice” Vaccine 16:6-8 (1998).
Strelow et al, Role of the virion host shutoff (vhs) of herpes simplex virus type 1 in latency and pathogenesis J. of Virology 69:6779-6786 (1995).
Geiss et al, “Disruption of virion host shutoff activity improves the immunogenicity and protective capacity of: replication-incompetent herpes simplex virus type 1 vaccine strain” J. of Virology 74:11137-11144 (2000).
Huard et al, “Gene transfer to muscle using herpes simplex virus-based vectors” Neuromuscular Disorders 7:299-313 (1997)—Abstract only.
MacLean et al, “Herpes simplex virus type 1 deletion variants 1714 and 1716 pinpoint neurovirulence-related sequences in Glasgow strain 17+ between immediate early gene 1 and the ‘a’ sequence” J. Gen. Virology 72:631-639 (1991).
Chou et al, “Differential response of human cells to deletions and stop codons in theγ134.5 gene of herpes simplex virus” J. Virology 68:8304-8311 (1994).
Chou & Roizman, “Theγ134.5 gene of herpes simplex virus 1 precludes neuroblastoma cells from triggering total shutoff of protein synthesis characteristic of programmed cell death in neuronal cells” Proc. Natl. Acad. Sci. USA 89:3266-3270 (1992).
Gendler et al, “Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin” J. Biol. Chem. 265:15286-15293 (1990).
Aicher et al, “Successful retroviral mediated transduction of a reporter gene in human dendritic cells: Feasibility of therapy with gene-modified antigen presenting cells” Exp. Hematology 25:39-44 (1997).
Samaniego et al, “Functional interactions between herpes simplex virus immediate-early proteins during infection: Gene expression as a consequence of ICP27 and different domains of ICP4” J. Virology 69:5705-5715 (1995).
Zitvogel et al, “Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines” J. Exp. Med. 183:87-97 (1996).
Celluzzi et al, “Peptide-pulsed dendritic cells induce antigen-specific, CTL-mediated protective tumor immunity” J. Exp. Med. 183:283-297 (1996).
Reeves et al, “Retroviral transduction of human dendritic cells with a tumor-associated antigen gene” Cancer Research 56:5672-5677 (1996).
Arthur et al, “A comparison of gene transfer methods in human dendritic cells” Cancer Gene Therapy 4:17-25 (1997).
Ace et al, “Construction and characterization of a herpes simplex virus type 1 mutant unable to transinduce immediate-early gene expression” J. Virology 63:2260-2269 (1989).
Smith et al, “Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression” Virology 186:74-66 (1992).
Rice & Knipe, “Genetic evidence for two distinct transactivation functions of the herpes simplex virus α protein ICP27” J. Virology 64:1704-1715 (1990).
DeLuca et al, “Isolation and characterization of deletion mutants of herpes simplex virus type 1 in the gene encoding immediate-early regulatory protein ICP4” J. Virology 56:558-570 (1985).
McFarlane et al, “Hexamethylene bisacetamide stimulates herpes simplex virus immediate early gene expression in the absence of trans-induction by Vmw65” J. Gen. Virology 73:285-292 (1992).
Lokensgard et al, “Long-term promoter activity during herpes simplex virus latency” J. Virology 68:7148-7158 (1994).
MacLean et al, “Investigation of herpes simplex virus type 1 genes encoding multiply inserted membrane proteins” J. Gen. Virology 72:897-906 (1991).
Gossen & Bujard, “Tight control of gene expression in mammalian cells by tetracycline-responsive promoters” Proc. Natl. Acad. Sci. USA 89:5547-5551 (1992).
Smiley & Duncan, “Truncation of the C-terminal acidic transcriptional activation domain of herpes simplex virus VP16 produces a phenotype similar to that of the in1814 linker insertion mutation” J. Virology 71:6191-6193 (1997).
Girolomoni & Ricciardi-Castagnoli, “Dendritic cells hold promise for immunotherapy” Immunology Today 18(3):102-104 (1997).
Dilloo et al, “A novel herpes vector for the high-efficiency transduction of normal and malignant human hematopoietic cells” Blood 89:119-127 (1997).
Caux et al. “GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells” Nature 360:258-261 (1992).
Coffin & Latchman In: Genetic Manipulation of the Nervous System, pp. 99-114 Academic Press, London (1996).
Goldsmith et al. “Infected cell protein (ICP) 47 enhances herpes simplex virus neurovirulence by blocking the CD8+T cell response” J. Exp. Med. 87:341-348 (1998).
Gough & Murray “Expression of the hepatitis B virus surface, core and E antigen genes by stable rat and mouse cell lines” J. Mol. Biol. 162:43-67 (1982).
Inaba et al. “Identification of proliferating dendritic cell precursors in mouse blood” J. Exp. Med. 175:11057-1167 (1992).
Jones et al. “Mutational analysis of the herpes simplex virus virion host shutoff protein: Evidence that vhs functions in the absence of other viral proteins” J. Virology 69:4863-4871 (1995).
Kruse et al. “Mature dendritic cells infected with herpes simplex virus type 1 exhibit inhibited T-cell stimulatory capacity” J. Virology 74:7127-7136 (2000).
Salio et al. “Inhibition of dendritic cell maturati
Biovex Limited
Mosher Mary E.
LandOfFree
Herpes viruses for immune modulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Herpes viruses for immune modulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Herpes viruses for immune modulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3643846